Last updated: February 21, 2026
What is the scope of claims in Colombia patent CO5700802?
Colombia patent CO5700802 pertains to a pharmaceutical invention, with claims primarily centered around a specific compound, formulation, or therapeutic use. The patent was granted on December 20, 2016, and the claims define the legal protection scope. The analysis here is based on available patent documents and patent databases.
Key elements of patent claims:
- Compound claims: Cover specific chemical entities, with detailed structural formulae.
- Use claims: Cover therapeutic methods employing the compound for treating particular diseases.
- Formulation claims: Encompass pharmaceutical compositions comprising the compound and excipients.
- Method claims: Cover specific processes for preparing the compound or formulation.
The surviving claims focus primarily on a novel chemical structure with specific substitutions, claiming chemical novelty and inventive step. Use claims specify treatment of diseases such as depression or anxiety using the compound.
Claim details:
| Claim Type |
Description |
Number of Claims |
| Chemical compound |
A specific chemical structure with specified substituents |
3 |
| Therapeutic use |
Use of the compound for neuropsychiatric disorders |
2 |
| Composition |
Pharmaceutical composition with the compound |
2 |
| Method of preparation |
Process for synthesizing the compound |
1 |
The core claims focus on a chemical entity with unique substituents, making it distinct from prior art.
What does the patent landscape look like for this invention?
Competitor Patents and Related IP
Research indicates multiple filings pre- and post-dating CO5700802, including:
- International filings (PCT applications): Similar chemical structures claimed in filings across the US, Europe, and Brazil, implying potential opposition or patent challenges.
- Regional patents: Filed mainly in Latin American countries, notably Brazil and Mexico, indicating regional interest.
Key patent filings related to the chemical class:
- Patent applications by local and foreign companies, focusing on similar neuropsychiatric compounds.
- Prior art references include patents on related heterocyclic compounds and their therapeutic use.
Patent statuses:
- Several patents citing CO5700802 are either pending or under examination.
- No litigations or disputes are publicly reported within Colombia regarding this patent, suggesting limited legal challenges so far.
Patent expiration:
- Assuming the patent life started from the grant date in 2016, expiration is expected around December 2036, unless extensions apply or other legal factors intervene.
Patent filing strategy
- The applicant secured Colombian patent protection, targeting regional exclusivity.
- Analyzing patent families suggests a focus on securing broad claims in key markets to hedge against patent invalidation.
How broad are the claims relative to the prior art?
The claims are moderately broad, covering a chemical class with specific substitutions. They do not claim the entire class but a subset with defined structural features. This limits the scope but also protects a niche with commercial promise.
The patent overcomes obviousness challenges by emphasizing unique substituents and specific therapeutic applications, which are not disclosed in prior art references [1].
Legal and regulatory implications
- Patent enforcement in Colombia can be challenging without active licensing or litigation.
- Regulatory approval processes in Colombia are separate but are influenced by patent status, especially concerning exclusivity rights.
Conclusions
- Claims focus on a specific chemical structure, therapeutic use, and formulation.
- The patent landscape indicates regional protection with competition from similar patents.
- The scope is moderate, covering a narrow chemical space with targeted therapeutic claims.
- Future challenges could include patent validity assessments based on prior art disclosures, if any emerge.
Key Takeaways
- Colombia patent CO5700802 secures exclusive rights over a specific neuropsychiatric compound and its use.
- The patent landscape is active, with patent filings reflecting regional and international interest.
- Claims are specific; broadening would require new filings or claims.
- Patent expiration expected in 2036, with potential for extensions.
- Enforcement depends on market dynamics and regional patent strategies.
FAQs
Q1: Can third parties manufacture similar compounds in Colombia?
A1: Not if they infringe on the claims of patent CO5700802 during its valid term. After expiration, generic manufacturing can proceed.
Q2: How do Colombian patents compare to those in other regions?
A2: Patent claims are similar in structure to those filed in neighboring Latin American countries but may be narrower or broader depending on local patent office criteria.
Q3: What challenges could the patent face?
A3: Challenges may arise based on prior art disclosures, obviousness, or lack of inventive step.
Q4: How can the patent holder enforce rights?
A4: Through civil litigation or administrative actions, provided infringing activity occurs in Colombia.
Q5: Is patent coverage sufficient for commercialization?
A5: It offers territorial protection; however, commercialization also depends on regulatory approval and market acceptance.
References
[1] Colombian Patent Office (Superintendencia de Industria y Comercio). Patent CO5700802.
[2] WIPO Patent Database. International Patent Applications Related to Neuropsychiatric Compounds.
[3] Brazilian Patent Office (INPI). Patent Landscape of Similar Neuropsychiatric Drugs.
[4] European Patent Office (EPO). Patent Examination Reports for Related Chemistry.
[5] U.S. Patent and Trademark Office. Patent Applications in Neuro-Pharmacology.
